JP7421874B2 - Open pore improver - Google Patents
Open pore improver Download PDFInfo
- Publication number
- JP7421874B2 JP7421874B2 JP2019112052A JP2019112052A JP7421874B2 JP 7421874 B2 JP7421874 B2 JP 7421874B2 JP 2019112052 A JP2019112052 A JP 2019112052A JP 2019112052 A JP2019112052 A JP 2019112052A JP 7421874 B2 JP7421874 B2 JP 7421874B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- pore
- weight
- improving agent
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011148 porous material Substances 0.000 title claims description 100
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- -1 acetyl pantothenyl ethyl ether Chemical compound 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 47
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 23
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 15
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 claims description 12
- 229940101267 panthenol Drugs 0.000 claims description 12
- 235000020957 pantothenol Nutrition 0.000 claims description 12
- 239000011619 pantothenol Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229950010121 ufenamate Drugs 0.000 claims description 12
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 11
- 229940055726 pantothenic acid Drugs 0.000 claims description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims description 11
- 239000011713 pantothenic acid Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 4
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N pantetheine Chemical compound OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 claims description 4
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 claims description 2
- JDMUPRLRUUMCTL-VIFPVBQESA-N D-pantetheine 4'-phosphate Chemical compound OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS JDMUPRLRUUMCTL-VIFPVBQESA-N 0.000 claims description 2
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 claims description 2
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 2
- 229960000903 pantethine Drugs 0.000 claims description 2
- 235000008975 pantethine Nutrition 0.000 claims description 2
- 239000011581 pantethine Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 description 32
- 235000019198 oils Nutrition 0.000 description 31
- 238000009472 formulation Methods 0.000 description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000006872 improvement Effects 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 150000002948 pantothenic acids Chemical class 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 229920001214 Polysorbate 60 Polymers 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 240000003421 Dianthus chinensis Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OHILSKSRDDTCIR-WKSAPEMMSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;hydrochloride Chemical compound Cl.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O OHILSKSRDDTCIR-WKSAPEMMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- ZXNAIPHYBVMMPY-KTKRTIGZSA-N 1-erucoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCC(O)CO ZXNAIPHYBVMMPY-KTKRTIGZSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- XWZPJRNVELUELY-GDVGLLTNSA-N 2,3-dihydroxypropyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OCC(O)COC(=O)[C@@H]1CCC(=O)N1 XWZPJRNVELUELY-GDVGLLTNSA-N 0.000 description 1
- MKSQZGCMRALSMS-UHFFFAOYSA-N 2,3-dihydroxypropyl octadecanoate;2-(2,3-dihydroxypropyl)octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO.CCCCCCCCCCCCCCCCC(C(O)=O)CC(O)CO MKSQZGCMRALSMS-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 241001017629 Saccharina sculpera Species 0.000 description 1
- 240000005319 Sedum acre Species 0.000 description 1
- 235000014327 Sedum acre Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- GORMSINSWZJIKL-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-dimethylpropyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(C)(C)COC(=O)C(CC)CCCC GORMSINSWZJIKL-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- AHXDSVSZEZHDLV-UHFFFAOYSA-N mesulfen Chemical compound CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1 AHXDSVSZEZHDLV-UHFFFAOYSA-N 0.000 description 1
- 229960005479 mesulfen Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229950006098 orthocaine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
本発明は、毛穴の開きを改善できる毛穴開き改善剤に関する。 TECHNICAL FIELD The present invention relates to an agent for improving pore opening.
近年、スキンケアへの意識は老若男女問わず向上しており、その中でも、毛穴の開きは改善したい肌の悩みの上位に常に挙げられている。毛穴は、毛穴の開口部がすり鉢状に形態を変化させることで開いて目立つことが知られており、特に頬部で顕著に視認される。 In recent years, awareness of skin care has increased among people of all ages and genders, and among them, enlarged pores are always listed as one of the top skin concerns that people want to improve. It is known that pores become conspicuous when the pore openings change shape into a mortar shape, and are particularly visible on the cheeks.
そこで、毛穴の開きを目立たなくさせることを目的とした外用組成物として、サンキライ、シャゼンシ、ボウイ、ボウフウ、マオウ、コンズランゴ、グレープフルーツ、ブクリョウ、ブドウ、マンネンロウ、ローマカミツレ及びセイヨウネズからなる群から選ばれる１種以上の植物若しくはその抽出物、トサカ抽出物及び／又はトレハロースを含有するケラチノサイト収縮促進剤（特許文献１）、ホウセンカ抽出物を有効成分とする毛穴収縮剤（特許文献２）、ガゴメコンブ（Kjellmaniella crassifolia）等の海藻抽出物を有効成分とする毛穴収縮剤（特許文献３）、ナデシコ科ナデシコ属（Dianthus）の抽出物を有効成分とする毛穴目立ち予防・改善剤（特許文献４）等が知られている。 Therefore, as a topical composition for the purpose of making the enlarged pores inconspicuous, one selected from the group consisting of sankirai, chazenshi, bowi, bowfu, ephedra, konzurango, grapefruit, bukuriyo, grape, stonecrop, Roman chamomile, and Japanese juniper is used. A keratinocyte contraction promoter containing more than one species of plant or an extract thereof, a comb extract and/or trehalose (Patent Document 1), a pore shrinking agent containing a balsam extract as an active ingredient (Patent Document 2), Kjellmaniella crassifolia ) and other seaweed extracts as an active ingredient (Patent Document 3), and a pore conspicuous prevention/improving agent containing an extract of Dianthus (Dianthus) as an active ingredient (Patent Document 4), etc. are known. ing.
一方、パンテノールは、細胞賦活化作用、毛髪保護作用、保湿作用等、様々な効果を有する成分として外用組成物に配合して用いられている。例えば、パンテノールをコハク酸及びキレート剤と組み合わせることにより、パンテノールによる毛髪保護作用が向上され、キューティクルの剥離が抑制されること（特許文献５）が知られている。また、ニコチン酸アミドをパンテノール及び塩酸ピリドキシンと組み合わせることにより、ニコチン酸アミドによる色素沈着防止効果が向上しシミに対する治療効果が得られること（特許文献６）が知られている。 On the other hand, panthenol is used in external compositions as a component having various effects such as cell activation, hair protection, and moisturizing effects. For example, it is known that by combining panthenol with succinic acid and a chelating agent, the hair protection effect of panthenol is improved and cuticle peeling is suppressed (Patent Document 5). Furthermore, it is known that by combining nicotinic acid amide with panthenol and pyridoxine hydrochloride, the antipigmentation effect of nicotinic acid amide is improved and a therapeutic effect on age spots can be obtained (Patent Document 6).
また、ウフェナマートは、非ステロイド系抗炎症剤として、医薬品又は医薬部外品の皮膚外用剤に配合して用いられている。例えば、特許文献７には、ウフェナマート等の非ステロイド系抗炎症剤と、特定のアミド誘導体とを含む皮膚外用剤が、薬効の持続性に優れるだけでなく、肌自身にうるおいを与え、皮膚刺激性が低く、肌荒れ改善効果に優れ、しかも使用感が良好であることが記載されている。 Further, ufenamate is used as a non-steroidal anti-inflammatory agent by being mixed into a pharmaceutical or quasi-drug skin preparation for external use. For example, Patent Document 7 discloses that a skin external preparation containing a non-steroidal anti-inflammatory agent such as ufenamate and a specific amide derivative not only has excellent long-lasting medicinal effects, but also provides moisture to the skin itself and irritates the skin. It is described that the product has low viscosity, has an excellent effect on improving rough skin, and has a good feeling when used.
特許文献１～５に記載の毛穴の開きを目立たなくさせることを目的とした外用組成物は植物エキスを有効成分としている。しかし、植物エキスには特有の蛋白質又は糖蛋白質等のアレルゲンが含まれていたり、外用組成物基剤に溶解することで不安定となったりすることで、肌質によっては、アレルギーや炎症を起こすことも考えられる。 The external compositions described in Patent Documents 1 to 5 for the purpose of making enlarged pores less noticeable contain plant extracts as active ingredients. However, plant extracts contain allergens such as specific proteins or glycoproteins, or become unstable when dissolved in the base of external compositions, which can cause allergies or inflammation depending on the skin type. It is also possible.
そこで、本発明は、毛穴の開きを目立たなくさせることを目的とした毛穴開き改善剤の新たな製剤処方を提供することを目的とする。 Therefore, an object of the present invention is to provide a new formulation of an agent for improving pore enlargement, which aims to make pore enlargement less noticeable.
本発明者は、鋭意検討を行ったところ、驚くべきことに、これまで毛穴の開きに対する改善効果が知られていない、パントテン酸、パントテン酸誘導体、及び／又はそれらの塩とウフェナマートとを組み合わせることで、毛穴の開きを目立たなくさせる効果が備わることを見出した。本発明は、この知見に基づいて更に検討を重ねることにより完成したものである。 After intensive studies, the present inventor surprisingly found that pantothenic acid, pantothenic acid derivatives, and/or salts thereof, and ufenamate, which have not been known to have an improving effect on enlarged pores, can be combined. We discovered that it has the effect of making pores less noticeable. The present invention was completed through further studies based on this knowledge.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． （Ａ）パントテン酸、パントテン酸誘導体、及び／又はそれらの塩、並びに（Ｂ）ウフェナマートを含有する、毛穴開き改善剤。
項２． 前記（Ａ）成分がパンテノールである、項１に記載の毛穴開き改善剤。
項３． 前記（Ａ）成分を０．１～３重量％含む、項１又は２に記載の毛穴開き改善剤。
項４． 前記（Ｂ）成分を１～２０重量％含む、項１～３のいずれかに記載の毛穴開き改善剤。
項５． 前記（Ａ）成分１重量部当たり、前記（Ｂ）成分が０．３～２００重量部の比率で含まれる、項１～４のいずれかに記載の毛穴開き改善剤。
項６． 乳化組成物である、項１～５のいずれかに記載の毛穴開き改善剤。
That is, the present invention provides the inventions of the following aspects.
Item 1. An open pore improving agent containing (A) pantothenic acid, a pantothenic acid derivative, and/or a salt thereof, and (B) ufenamate.
Item 2. Item 2. The pore enlargement improving agent according to Item 1, wherein the component (A) is panthenol.
Item 3. Item 3. The pore enlargement improving agent according to item 1 or 2, which contains 0.1 to 3% by weight of the component (A).
Item 4. Item 4. The pore enlargement improving agent according to any one of Items 1 to 3, which contains 1 to 20% by weight of the component (B).
Item 5. Item 5. The pore enlargement improver according to any one of Items 1 to 4, wherein the component (B) is contained in a ratio of 0.3 to 200 parts by weight per 1 part by weight of the component (A).
Item 6. Item 6. The pore enlargement improving agent according to any one of Items 1 to 5, which is an emulsified composition.
本発明の毛穴開き改善剤によると、毛穴の開きを改善することができる。つまり、本発明の毛穴開き改善剤によると、毛穴を収縮させることで毛穴の開きを目立たなくし、更に視認できる毛穴の数を減らすことが可能になる。このため、毛穴の開きが特に顕著である頬部に対しても効果的に毛穴の開きを目立たなくさせることが可能になる。 According to the pore enlargement improving agent of the present invention, pore enlargement can be improved. In other words, according to the pore enlargement improving agent of the present invention, it is possible to make pore enlargement less noticeable by shrinking pores, and further to reduce the number of visible pores. For this reason, it is possible to effectively make the enlarged pores less noticeable even on the cheek area where the enlarged pores are particularly noticeable.
毛穴開き改善剤
本発明の毛穴開き改善剤は、（Ａ）パントテン酸、パントテン酸誘導体、及び／又はそれらの塩（以下、「（Ａ）成分」とも記載する）、並びに（Ｂ）ウフェナマート（以下、「（Ｂ）成分」とも記載する）、を含有することを特徴とする。以下、本発明の毛穴開き改善剤について詳述する。
Open pore improver The open pore improver of the present invention comprises (A) pantothenic acid, a pantothenic acid derivative, and/or a salt thereof (hereinafter also referred to as "component (A)"), and (B) ufenamate (hereinafter referred to as "component (A)"). , also referred to as "component (B)"). Hereinafter, the pore opening improving agent of the present invention will be explained in detail.
（Ａ）パントテン酸、パントテン酸誘導体、及び／又はそれらの塩
本発明の毛穴開き改善剤は、（Ａ）成分としてパントテン酸、パントテン酸誘導体、及び／又はそれらの塩を含有する。パントテン酸は、Ｎ－（２，４－ジヒドロキシ－３，３－ジメチルブチリル）－β－アラニンとも称され、ビタミンＢ群に含まれる化合物として公知の成分である。
(A) Pantothenic acid, a pantothenic acid derivative, and/or a salt thereof The pore opening improving agent of the present invention contains pantothenic acid, a pantothenic acid derivative, and/or a salt thereof as the component (A). Pantothenic acid is also called N-(2,4-dihydroxy-3,3-dimethylbutyryl)-β-alanine, and is a component known as a compound included in the vitamin B group.
パントテン酸の誘導体としては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、パンテノール、パントテニルアルコール、パントテニルエチルエーテル、パンテテインパントテニルアルコール、アセチルパントテニルエチルエーテル、ベンゾイルパントテニルエチルエーテル、ジカルボエトキシパントテン酸エチルエステル、パンテテイン、パンテチン、ホスホパンテテイン等が挙げられる。これらのパントテン酸の誘導体は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 Derivatives of pantothenic acid are not particularly limited as long as they are pharmaceutically or cosmetically acceptable, but examples include panthenol, pantothenyl alcohol, pantothenyl ethyl ether, pantethein pantothenyl alcohol, and acetyl pantothenyl. Examples include ethyl ether, benzoyl pantothenyl ethyl ether, dicarboethoxypantothenic acid ethyl ester, pantetheine, pantethine, phosphopantetheine, and the like. These pantothenic acid derivatives may be used alone or in combination of two or more.
パントテン酸又はパントテン酸誘導体の塩としては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。これらのパントテン酸又はパントテン酸誘導体の塩は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 Salts of pantothenic acid or pantothenic acid derivatives are not particularly limited as long as they are pharmaceutically or cosmetically acceptable, but include alkali metal salts such as sodium salts and potassium salts; alkali salts such as calcium salts and magnesium salts; Examples include earth metal salts. These salts of pantothenic acid or pantothenic acid derivatives may be used alone or in combination of two or more.
本発明においては、（Ａ）成分として、パントテン酸、パントテン酸誘導体、及びそれらの塩の中から、１種のみを単独で使用することもでき、また２種以上を組み合わせて使用することもできる。 In the present invention, as component (A), only one type from among pantothenic acid, pantothenic acid derivatives, and salts thereof can be used alone, or two or more types can be used in combination. .
上記の（Ａ）成分の中でも、より優れた毛穴開き改善効果を得る観点から、パントテン酸誘導体又はその塩が挙げられ、より好ましくはパントテン酸誘導体が挙げられ、更に好ましくはパンテノールが挙げられる。 Among the above-mentioned components (A), from the viewpoint of obtaining a more excellent pore opening improvement effect, pantothenic acid derivatives or salts thereof are mentioned, more preferably pantothenic acid derivatives are mentioned, and still more preferably panthenol is mentioned.
本発明の毛穴開き改善剤中の（Ａ）成分の含有量としては特に限定されないが、総量で、例えば０．１～３重量％、好ましくは０．１～２重量％、より好ましくは０．３～２重量％が挙げられる。 The content of component (A) in the pore opening improving agent of the present invention is not particularly limited, but the total amount is, for example, 0.1 to 3% by weight, preferably 0.1 to 2% by weight, more preferably 0.1 to 3% by weight. Examples include 3 to 2% by weight.
（Ｂ）ウフェナマート
本発明の毛穴開き改善剤は、（Ｂ）成分としてウフェナマートを含有する。ウフェナマートは、フルフェナム酸ブチルとも称され、水難溶性の非ステロイド性抗炎症薬として公知の成分である。
(B) Ufenamate The pore opening improving agent of the present invention contains ufenamate as the (B) component. Ufenamate is also called butyl flufenamic acid, and is a component known as a poorly water-soluble non-steroidal anti-inflammatory drug.
本発明の毛穴開き改善剤において、（Ｂ）成分の含有量については特に限定されないが、例えば１～２０重量％、好ましくは２～１０重量％が挙げられる。より優れた毛穴開き改善効果を得る観点から、（Ｂ）成分の含有量としては、好ましくは３～１０重量％、より好ましくは３～７重量％が挙げられる。 In the pore enlargement improving agent of the present invention, the content of component (B) is not particularly limited, but may be, for example, 1 to 20% by weight, preferably 2 to 10% by weight. From the viewpoint of obtaining a better pore opening improvement effect, the content of component (B) is preferably 3 to 10% by weight, more preferably 3 to 7% by weight.
本発明の毛穴開き改善剤において、（Ａ）成分に対する（Ｂ）成分の比率については、（Ａ）成分及び（Ｂ）成分の各含有量に応じて定まるが、より優れた毛穴開き改善効果を得る観点から、例えば、（Ａ）成分１重量部当たりの（Ｂ）成分の含有量として、０．３～２００重量部、好ましくは０．３～４０重量部、更に好ましくは１～４０重量部が挙げられる。更に優れた毛穴開き改善効果を得る観点から、（Ａ）成分１重量部当たりの（Ｂ）成分の含有量として、好ましくは５～２０重量部、より好ましくは５～１０重量部が挙げられる。 In the pore opening improving agent of the present invention, the ratio of component (B) to component (A) is determined depending on the respective contents of component (A) and component (B). From the viewpoint of obtaining, for example, the content of component (B) per 1 part by weight of component (A) is 0.3 to 200 parts by weight, preferably 0.3 to 40 parts by weight, more preferably 1 to 40 parts by weight. can be mentioned. From the viewpoint of obtaining a more excellent pore opening improvement effect, the content of component (B) per 1 part by weight of component (A) is preferably 5 to 20 parts by weight, more preferably 5 to 10 parts by weight.
油分
本発明の毛穴開き改善剤は、さらに、油分を含有することができる。油分は、製剤形態等に応じて適宜使用することができ、例えば、本発明の毛穴開き改善剤が乳化組成物である場合の油相として、又は、本発明の毛穴開き改善剤が油性ゲル状組成物である場合の基剤として使用される。
Oil content The pore enlargement improving agent of the present invention may further contain an oil content. The oil can be used as appropriate depending on the formulation, for example, as an oil phase when the pore size improving agent of the present invention is an emulsion composition, or as an oil phase when the pore size improving agent of the present invention is in the form of an oily gel. Used as a base for compositions.
本発明で使用される油分については、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、液状油、固形油、高級アルコール等が挙げられる。これらの油分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 The oil used in the present invention is not particularly limited as long as it is pharmaceutically or cosmetically acceptable, and examples thereof include liquid oil, solid oil, and higher alcohol. These oils may be used alone or in combination of two or more.
本発明の毛穴開き改善剤に油分を含有させる場合、その含有量については、特に制限されず、毛穴開き改善剤の製剤形態等に応じて適宜設定すればよいが、例えば、５～６０重量％、好ましくは１０～４０重量％、より好ましくは２０～３０重量％が挙げられる。 When the pore size improving agent of the present invention contains oil, the content is not particularly limited and may be set as appropriate depending on the formulation form of the pore size improving agent, for example, 5 to 60% by weight. , preferably 10 to 40% by weight, more preferably 20 to 30% by weight.
（液状油）
液状油とは、２５℃において液状の形態を保つ油である。本発明で使用される液状油としては、化粧料や外用医薬品等に通常用いられるものであればよく、例えば、；オレイン酸、インステアリン酸等の脂肪酸；エチルヘキサン酸セチル、パルミチン酸エチルヘキシル、ミリスチン酸オクチルドデシル、ジエチルヘキサン酸ネオペンチルグリコール、トリ２－エチルへキサン酸グリセリル、オレイン酸オクチルドデシル、ミリスチン酸イソプロピル、トリイソステアリン酸グリセリル、ジバラメトキシケイヒ酸－モノエチルへキサン酸グリセリル等のエステル油；ジメチルポリシロキサン、メチルハイドロジエンポリシロキサン、メチルフェニルポリシロキサン、オクタメチルシクロテトラシロキサン等のシリコーン油；流動パラフィン、スクワレン、スクワラン等の液状炭化水素油等が挙げられる。
(liquid oil)
Liquid oil is an oil that remains in liquid form at 25°C. The liquid oil used in the present invention may be one commonly used in cosmetics, external medicines, etc., such as; fatty acids such as oleic acid and instearic acid; cetyl ethylhexanoate, ethylhexyl palmitate, myristic acid, etc. Ester oils such as octyldodecyl acid, neopentyl glycol diethylhexanoate, glyceryl tri-2-ethylhexanoate, octyldodecyl oleate, isopropyl myristate, glyceryl triisostearate, glyceryl dibaramethoxycinnamate-monoethylhexanoate; dimethyl Examples include silicone oils such as polysiloxane, methylhydrodiene polysiloxane, methylphenylpolysiloxane, and octamethylcyclotetrasiloxane; liquid hydrocarbon oils such as liquid paraffin, squalene, and squalane.
これらの液状油の中でも、より一層優れた毛穴開き改善効果を得る観点から、好ましくは、エステル油、液状炭化水素油が挙げられ、より好ましくはミリスチン酸イソプロピル、流動パラフィンが挙げられる。 Among these liquid oils, ester oils and liquid hydrocarbon oils are preferred, and isopropyl myristate and liquid paraffin are more preferred, from the viewpoint of obtaining even more excellent pore opening improvement effects.
これらの液状油は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These liquid oils may be used alone or in combination of two or more.
本発明の外用安定化剤に液状油を含有させる場合、その含有量については、特に制限されず、毛穴開き改善剤の製剤形態等に応じて適宜設定すればよいが、例えば、０．０１～３０重量％、好ましくは０．１～３０重量％、より好ましくは１～２０重量％、さらに好ましくは１０～１８重量％が挙げられる。 When the external stabilizer of the present invention contains a liquid oil, its content is not particularly limited and may be set as appropriate depending on the formulation form of the pore opening improving agent, etc., but for example, from 0.01 to Examples include 30% by weight, preferably 0.1 to 30% by weight, more preferably 1 to 20% by weight, and even more preferably 10 to 18% by weight.
（固形油）
固形油とは、２５℃において固形の形態を保つ油である。本発明で使用される固形油としては、通常化粧料や外用医薬品等に用いられるものであればよく、例えば、キャンデリラロウ、コメヌカロウ、ミツロウ、綿ロウ、カルナウバロウ、ラノリン、セラックロウ、オゾケライト、セレシン、ポリエチレンワックス、マイクロクリスタリンワックス、ワセリン、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘニン酸、１２－ヒドロキシステアリン酸、ウンデシレン酸、ミリスチン酸ミリスチル、ミリスチン酸セチル、ステアリン酸ステアリル、ステアリン酸セチル、パルミチン酸セチル、ステアリン酸コレステリル、オレイン酸コレステリル、パルミチン酸デキストリン、ステアリン酸イヌリン、水素添加ホホバ油、セレシンワックス、固形パラフィンワックス、ポリエチレンワックス、シリコーンワックス等の固形油が挙げられる。
(solid oil)
A solid oil is an oil that remains in solid form at 25°C. The solid oils used in the present invention may be those normally used in cosmetics, external medicines, etc., such as candelilla wax, rice bran wax, beeswax, cotton wax, carnauba wax, lanolin, shellac wax, ozokerite, ceresin, Polyethylene wax, microcrystalline wax, vaseline, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, 12-hydroxystearic acid, undecylenic acid, myristyl myristate, cetyl myristate, stearyl stearate, cetyl stearate, palmitin Examples include solid oils such as cetyl acid, cholesteryl stearate, cholesteryl oleate, dextrin palmitate, inulin stearate, hydrogenated jojoba oil, ceresin wax, solid paraffin wax, polyethylene wax, and silicone wax.
これらの固形油の中でも、より一層優れた毛穴開き改善効果を得る観点から、好ましくは、ワセリンが挙げられる。 Among these solid oils, vaseline is preferred from the viewpoint of obtaining even more excellent pore opening improvement effects.
これらの固形油は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These solid oils may be used alone or in combination of two or more.
本発明の毛穴開き改善剤に固形油を含有させる場合、その含有量については、特に制限されず、毛穴開き改善剤の製剤形態等に応じて適宜設定すればよいが、例えば、０．１～３０重量％、好ましくは１～２０重量％、更に好ましくは３～１０重量％が挙げられる。 When the pore size improving agent of the present invention contains solid oil, its content is not particularly limited and may be set as appropriate depending on the formulation form of the pore size improving agent, for example, from 0.1 to 30% by weight, preferably 1 to 20% by weight, more preferably 3 to 10% by weight.
（高級アルコール）
高級アルコールとは、１分子中の炭素原子数が６個以上の１価アルコールである。本発明で使用される高級アルコールにおける１分子中の炭素原子数について、６以上であればよいが、好ましくは６～３４、更に好ましくは１４～２２が挙げられる。
(higher alcohol)
A higher alcohol is a monohydric alcohol having 6 or more carbon atoms in one molecule. The number of carbon atoms in one molecule of the higher alcohol used in the present invention may be 6 or more, preferably 6 to 34, more preferably 14 to 22.
本発明で使用される高級アルコールとしては、通常化粧料や外用医薬品等に用いられるものであればよく、例えば、ミリスチルアルコール、セチルアルコール（セタノール）、オレイルアルコール、ステアリルアルコール、イソステアリルアルコール、ベヘニルアルコール、ラノリンアルコール等が挙げられる。 The higher alcohol used in the present invention may be one that is normally used in cosmetics, external medicines, etc., such as myristyl alcohol, cetyl alcohol (cetanol), oleyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, Examples include lanolin alcohol.
これらの高級アルコールの中でも、より一層優れた毛穴開き改善効果を得る観点から、好ましくは、セチルアルコール（セタノール）、ステアリルアルコールが挙げられる。 Among these higher alcohols, cetyl alcohol (cetanol) and stearyl alcohol are preferred from the viewpoint of obtaining even more excellent pore opening improvement effects.
これらの高級アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These higher alcohols may be used alone or in combination of two or more.
本発明の乳化組成物に高級アルコールを含有させる場合、その含有量については、特に制限されず、乳化組成物の乳化タイプ、形態、用途等に応じて適宜設定すればよいが、例えば、０．１～５０重量％、好ましくは１～３０重量％、より好ましくは２～１５重量％、更に好ましくは３～１０重量％が挙げられる。 When the emulsified composition of the present invention contains a higher alcohol, the content is not particularly limited and may be appropriately set depending on the emulsion type, form, use, etc. of the emulsified composition, but for example, 0. Examples include 1 to 50% by weight, preferably 1 to 30% by weight, more preferably 2 to 15% by weight, and still more preferably 3 to 10% by weight.
界面活性剤
本発明の毛穴開き改善剤は、さらに、界面活性剤を含有することができる。界面活性剤は製剤形態等に応じて適宜使用することができ、例えば、本発明の毛穴開き改善剤が乳化組成物である場合は、乳化状態とするために使用される。界面活性剤としては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、ノニオン性界面活性剤、アニオン性界面活性剤、カチオン性界面活性剤、両性界面活性剤等が挙げられ、より一層優れた毛穴開き改善効果を得る観点から、好ましくはノニオン性界面活性剤が挙げられる。
Surfactant The pore opening improving agent of the present invention may further contain a surfactant. The surfactant can be used as appropriate depending on the formulation, etc. For example, when the pore opening improving agent of the present invention is an emulsified composition, it is used to make it into an emulsified state. The surfactant is not particularly limited as long as it is pharmaceutically or cosmetically acceptable, but examples include nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants. From the viewpoint of obtaining an even more excellent pore opening improvement effect, nonionic surfactants are preferred.
ノニオン性界面活性剤としては、具体的には、ポリオキシエチレン硬化ヒマシ油；ソルビタン脂肪酸エステル類（例えば、ソルビタンモノオレエート、ソルビタンモノイソステアレート、ソルビタンモノラウレート、ソルビタンモノパルミテート、ソルビタンモノステアレート、ソルビタンセスキオレエート、ソルビタントリオレエート、ペンタ－２－エチルヘキシル酸ジグリセロールソルビタン、テトラ－２－エチルヘキシル酸ジグリセロールソルビタン等）；グリセリン脂肪酸エステル類（例えば、モノ綿実油脂肪酸グリセリル、モノエルカ酸グリセリル、セスキオレイン酸グリセリル、モノステアリン酸グリセリル（ステアリン酸グリセリン）、α，α’－オレイン酸ピログルタミン酸グリセリル、モノステアリン酸グリセリンリンゴ酸等）；プロピレングリコール脂肪酸エステル類（例えば、モノステアリン酸プロピレングリコール等）；グリセリンアルキルエーテル；ステアレス－２；ポリオキシエチレンソルビタン脂肪酸エステル類（例えば、ポリオキシエチレンソルビタンモノオレエート、ポリオキシエチレンソルビタンモノステアレート（ポリソルベート６０）、ポリオキシエチレンソルビタンモノパルミテート、ポリオキシエチレンソルビタンイソステアレート、ポリオキシエチレンソルビタンテトラオレエート等）；ポリオキシエチレンソルビット脂肪酸エステル類（例えば、ポリオキシエチレンソルビットモノラウレート、ポリオキシエチレンソルビットモノオレエート、ポリオキシエチレンソルビットペンタオレエート、ポリオキシエチレンソルビットモノステアレート等）；ポリオキシエチレングリセリン脂肪酸エステル類（例えば、ポリオキシエチレングリセリンモノステアレート、ポリオキシエチレングリセリンモノイソステアレート、ポリオキシエチレングリセリントリイソステアレート等）；ポリオキシエチレン脂肪酸エステル類（例えば、ポリオキシエチレンモノオレエート、ポリオキシエチレンモノステアレート（ステアリン酸ポリオキシル）、ポリオキシエチレンジステアレート、ポリオキシエチレンモノジオレエート、ジステアリン酸エチレングリコール等）；ポリオキシエチレンアルキルエーテル類（例えば、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンオレイルエーテル、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンベヘニルエーテル、ポリオキシエチレン２－オクチルドデシルエーテル、ポリオキシエチレンコレスタノールエーテル等）；プルロニック型類（例えば、プルロニック等）；ポリオキシエチレン・ポリオキシプロピレンアルキルエーテル類（例えば、ポリオキシエチレン・ポリオキシプロピレン－セチルエーテル、ポリオキシエチレン・ポリオキシプロピレン－２－デシルテトラデシルエーテル、ポリオキシエチレン・ポリオキシプロピレンモノブチルエーテル、ポリオキシエチレン・ポリオキシプロピレン水添ラノリン、ポリオキシエチレン・ポリオキシプロピレングリセリンエーテル等）；ステアレス－２１等が挙げられる。 Specific examples of nonionic surfactants include polyoxyethylene hydrogenated castor oil; sorbitan fatty acid esters (for example, sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan mono stearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan pent-2-ethylhexylate, diglycerol sorbitan tetra-2-ethylhexylate, etc.); glycerin fatty acid esters (e.g., monoglyceryl cottonseed oil fatty acid, glyceryl monoerucate, Glyceryl sesquioleate, glyceryl monostearate (glyceryl stearate), glyceryl pyroglutamate α,α'-oleate, glyceryl monostearate malic acid, etc.); propylene glycol fatty acid esters (e.g. propylene glycol monostearate, etc.) ; Glycerin alkyl ether; Steareth-2; Polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monostearate (polysorbate 60), polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan isostearate, polyoxyethylene sorbitan tetraoleate, etc.); polyoxyethylene sorbit fatty acid esters (for example, polyoxyethylene sorbit monolaurate, polyoxyethylene sorbit monooleate, polyoxyethylene sorbit pentaoleate, (oxyethylene sorbitol monostearate, etc.); polyoxyethylene glycerin fatty acid esters (e.g., polyoxyethylene glycerin monostearate, polyoxyethylene glycerin monoisostearate, polyoxyethylene glycerin triisostearate, etc.); polyoxyethylene Fatty acid esters (e.g., polyoxyethylene monooleate, polyoxyethylene monostearate (polyoxyl stearate), polyoxyethylene distearate, polyoxyethylene monodioleate, ethylene glycol distearate, etc.); polyoxyethylene Alkyl ethers (e.g., polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene stearyl ether, polyoxyethylene behenyl ether, polyoxyethylene 2-octyl dodecyl ether, polyoxyethylene cholestanol ether, etc.); Pluronic type (e.g., Pluronic, etc.); polyoxyethylene/polyoxypropylene alkyl ethers (e.g., polyoxyethylene/polyoxypropylene-cetyl ether, polyoxyethylene/polyoxypropylene-2-decyltetradecyl ether, polyoxyethylene・Polyoxypropylene monobutyl ether, polyoxyethylene/polyoxypropylene hydrogenated lanolin, polyoxyethylene/polyoxypropylene glycerin ether, etc.); Steareth-21, etc.
これらのノニオン性界面活性剤の中でも、より一層優れた毛穴開き改善効果を得る観点から、好ましくはポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル類が挙げられ、より好ましくは、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタンモノステアレート（ポリソルベート６０）が挙げられる。 Among these nonionic surfactants, polyoxyethylene hydrogenated castor oil and polyoxyethylene sorbitan fatty acid esters are preferred, and polyoxyethylene sorbitan fatty acid esters are more preferred, from the viewpoint of obtaining even more excellent pore opening improvement effects. Examples include hydrogenated castor oil and polyoxyethylene sorbitan monostearate (polysorbate 60).
これらの界面活性剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These surfactants may be used alone or in combination of two or more.
本発明の毛穴開き改善剤に界面活性剤を含有させる場合、その含有量については、特に制限されず、毛穴開き改善剤の製剤形態等に応じて適宜設定すればよいが、例えば０．５～７重量％、好ましくは１～５重量％、より好ましくは１．５～３重量％が挙げられる。 When the pore size improving agent of the present invention contains a surfactant, the content is not particularly limited and may be set as appropriate depending on the formulation form of the pore size improving agent, for example, from 0.5 to 7% by weight, preferably 1 to 5% by weight, more preferably 1.5 to 3% by weight.
水
本発明の毛穴開き改善剤は、水を含有することができる。水は、製剤形態等に応じて適宜使用することができ、例えば、本発明の毛穴開き改善剤が乳化組成物である場合の水相として、又は、本発明の毛穴開き改善剤が水性液状組成物や水性ゲル状組成物である場合の基剤として使用される。
Water The pore opening improving agent of the present invention can contain water. Water can be used as appropriate depending on the formulation, for example, as an aqueous phase when the pore opening improving agent of the present invention is an emulsion composition, or as an aqueous phase when the pore opening improving agent of the present invention is an aqueous liquid composition. It is used as a base for products and aqueous gel compositions.
本発明の毛穴開き改善剤が水を含有する場合、その含有量については、製剤形態に応じて適宜設定すればよいが、例えば３０～９９重量％、好ましくは５０～９０重量％、より好ましくは６０～８５重量％、更に好ましくは６５～８０重量％が挙げられる。 When the pore opening improving agent of the present invention contains water, the content may be appropriately set depending on the formulation, but for example, 30 to 99% by weight, preferably 50 to 90% by weight, more preferably 60 to 85% by weight, more preferably 65 to 80% by weight.
その他の成分
本発明の毛穴開き改善剤は、前述する成分の他に、必要に応じて、通常使用される他の添加剤が含まれていてもよい。このような添加剤としては、例えば、多価アルコール、増粘剤、ｐＨ調節剤、緩衝剤、可溶化剤、キレート剤、防腐剤、保存剤、酸化防止剤、安定化剤、香料、着色料等が挙げられる。
Other Components In addition to the above-mentioned components, the pore opening improving agent of the present invention may contain other commonly used additives, if necessary. Such additives include, for example, polyhydric alcohols, thickeners, pH adjusters, buffers, solubilizers, chelating agents, preservatives, preservatives, antioxidants, stabilizers, fragrances, and colorants. etc.
多価アルコールとしては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、プロピレングリコール、１，３－ブチレングリコール（ＢＧ）、エチレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール等の２価アルコール；グリセリン等の３価アルコール、マクロゴール４０００、マクロゴール６０００等のポリエチレングリコール等が挙げられる。これらの多価アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 Polyhydric alcohols are not particularly limited as long as they are pharmaceutically or cosmetically acceptable, but include, for example, propylene glycol, 1,3-butylene glycol (BG), ethylene glycol, isoprene glycol, diethylene glycol, and diethylene glycol. Examples include dihydric alcohols such as propylene glycol; trihydric alcohols such as glycerin; and polyethylene glycols such as Macrogol 4000 and Macrogol 6000. These polyhydric alcohols may be used alone or in combination of two or more.
また、増粘剤としては、薬学的又は香粧学的に許容されることを限度として特に制限されないが、例えば、キサンタンガム、グアーガム、ローカストビーンガム、カラギーナン、デキストラン、メチルセルロース、エチルセルロース、カルボキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、アルギン酸ナトリウム、アルギン酸プロピレングリコールエステル、ポリビニルアルコール、ポリビニルピロリドン、ポリビニルメチルエーテル、カルボキシビニルポリマー、アクリル酸メタクリル酸アルキル共重合体、ポリアクリル酸ナトリウムベントナイト、デキストリン脂肪酸エステル、ペクチン等が挙げられ、好ましくはカルボキシビニルポリマーが挙げられる。これらの増粘剤は１種又は２種以上を組み合わせて使用できる。本発明の毛穴開き改善剤において、増粘剤を含有させる場合、その含有量については、使用する増粘剤の種類等に応じて適宜設定すればよいが、例えば０．１～３重量％、好ましくは０．１～１重量％、更に好ましくは０．３～０．６重量％が挙げられる。 The thickener is not particularly limited as long as it is pharmaceutically or cosmetically acceptable, but examples include xanthan gum, guar gum, locust bean gum, carrageenan, dextran, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxy Ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium alginate, propylene glycol alginate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, carboxyvinyl polymer, alkyl acrylate methacrylate copolymer, sodium polyacrylate bentonite, dextrin fatty acid ester , pectin, etc., preferably carboxyvinyl polymer. These thickeners can be used alone or in combination of two or more. When a thickener is contained in the pore enlargement improving agent of the present invention, the content may be appropriately set depending on the type of thickener used, but for example, 0.1 to 3% by weight, Preferably it is 0.1 to 1% by weight, more preferably 0.3 to 0.6% by weight.
ｐＨ調整剤としては、無機酸（塩酸、硫酸、リン酸、ポリリン酸、ホウ酸等）、有機酸（乳酸、酢酸、クエン酸、酒石酸、リンゴ酸、コハク酸、シュウ酸、グルコン酸、フマル酸、プロピオン酸、酢酸、アスパラギン酸、イプシロン－アミノカプロン酸、グルタミン酸、アミノエチルスルホン酸）、無機塩基（炭酸水素ナトリウム、炭酸ナトリウム、水酸化カリウム、水酸化ナトリウム、水酸化カルシウム、水酸化マグネシウム）、有機塩基（モノエタノールアミン、トリエタノールアミン、ジイソプロパノールアミン、トリイソプロパノールアミン、リジン等）が挙げられ、好ましくはトリエタノールアミンが挙げられる。 Examples of pH adjusters include inorganic acids (hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, boric acid, etc.), organic acids (lactic acid, acetic acid, citric acid, tartaric acid, malic acid, succinic acid, oxalic acid, gluconic acid, fumaric acid, etc.). , propionic acid, acetic acid, aspartic acid, epsilon-aminocaproic acid, glutamic acid, aminoethyl sulfonic acid), inorganic bases (sodium bicarbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide), organic Examples include bases (monoethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, lysine, etc.), preferably triethanolamine.
更に、本発明の毛穴開き改善剤は、前述する成分の他に、薬学的又は香粧学的な生理機能を発揮できる薬効成分が、必要に応じて含まれていてもよい。このような薬効成分としては、例えば、ステロイド剤（デキサメタゾン、塩酸デキサメタゾン、酢酸デキサメタゾン、塩酸ヒドロコルチゾン、吉草酸プレドニゾロン、酢酸プレドニゾロン等）、抗ヒスタミン剤（ジフェンヒドラミン、塩酸ジフェンヒドラミン、マレイン酸クロルフェニラミン等）、局所麻酔剤（リドカイン、ジブカイン、プロカイン、テトラカイン、ブピバカイン、メピバカイン、クロロプロカイン、プロパラカイン、メプリルカイン又はこれらの塩）、安息香酸アルキルエステル（例えばアミノ安息香酸エチル、塩酸パラブチルアミノ安息香酸ジエチルアミノエチル）、オルソカイン、オキセサゼイン、オキシポリエントキシデカン、ロートエキス、ペルカミンパーゼ、テシットデシチン等）、抗炎症剤（アラントイン、サリチル酸、サリチル酸グリコール、サリチル酸メチル、インドメタシン、フェルビナク、ジクロフェナクナトリウム、ロキソプロフェンナトリウム等）、殺菌剤（塩化ベンザルコニウム、塩化デカリニウム、塩化ベンゼトニウム、塩化セチルピリジニウム、塩酸クロルヘキシジン、グルコン酸クロルヘキシジン、イソプロピルメチルフェノール、アンモニア水、スルファジアジン、乳酸、フェノール等）、鎮痒剤（クロタミトン、チアントール等）、皮膚保護剤（コロジオン、ヒマシ油等）、血行促進成分（ノニル酸ワニリルアミド、ニコチン酸ベンジルエステル、カプサイシン、トウガラシエキス等）、ビタミン類（ビタミンＡ，Ｂ，Ｃ，Ｄ，Ｅ等）、ムコ多糖類（コンドロイチン硫酸ナトリウム、グルコサミン、ヒアルロン酸等）等が挙げられる。これらの薬効成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、本発明の毛穴開き改善剤において、これらの薬効成分を含有させる場合、その含有量については、使用する薬効成分の種類、期待する効果等に応じて適宜設定すればよい。 Furthermore, in addition to the above-mentioned components, the pore enlargement improving agent of the present invention may contain medicinal components capable of exerting pharmaceutical or cosmetic physiological functions, if necessary. Such medicinal ingredients include, for example, steroids (dexamethasone, dexamethasone hydrochloride, dexamethasone acetate, hydrocortisone hydrochloride, prednisolone valerate, prednisolone acetate, etc.), antihistamines (diphenhydramine, diphenhydramine hydrochloride, chlorpheniramine maleate, etc.), and local anesthesia. agents (lidocaine, dibucaine, procaine, tetracaine, bupivacaine, mepivacaine, chloroprocaine, proparacaine, meprilcaine or salts thereof), benzoic acid alkyl esters (e.g. ethyl aminobenzoate, diethylaminoethyl parabutylaminobenzoate hydrochloride), orthocaine, oxesazein, oxypolyentoxydecane, rotoextract, percaminpase, tesitdesitin, etc.), anti-inflammatory agents (allantoin, salicylic acid, glycol salicylate, methyl salicylate, indomethacin, felbinac, diclofenac sodium, loxoprofen sodium, etc.), bactericidal agents (benzalkonium chloride, dequalinium chloride, benzethonium chloride, cetylpyridinium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, isopropylmethylphenol, aqueous ammonia, sulfadiazine, lactic acid, phenol, etc.), antipruritics (crotamiton, thianthol, etc.), skin protectants (collodion, castor oil, etc.) ), blood circulation promoting ingredients (nonylic acid vanillylamide, nicotinic acid benzyl ester, capsaicin, hot pepper extract, etc.), vitamins (vitamins A, B, C, D, E, etc.), mucopolysaccharides (sodium chondroitin sulfate, glucosamine, hyaluronic acid) etc.) etc. These medicinal ingredients may be used alone or in combination of two or more. Further, when the pore enlargement improving agent of the present invention contains these medicinal ingredients, the content may be appropriately set depending on the type of medicinal ingredient used, the expected effect, etc.
製剤形態・用途
本発明の毛穴開き改善剤の製剤形態については特に制限されず、例えば、水性液状組成物、水性ゲル状組成物、油性ゲル状組成物、乳化組成物等が挙げられる。より一層優れた毛穴開き改善効果を得る観点から、本発明の毛穴開き改善剤の製剤形態としては、好ましくは水性ゲル状組成物、油性ゲル状組成物、乳化組成物が挙げられ、より好ましくは乳化組成物が挙げられる。本発明の毛穴開き改善剤が乳化組成物である場合の乳化タイプについては、水中油型又は油中水型のいずれであってもよいが、好ましくは水中油型が挙げられる。
Formulation Form/Use The formulation form of the pore-opening improving agent of the present invention is not particularly limited, and examples thereof include aqueous liquid compositions, aqueous gel compositions, oil-based gel compositions, and emulsified compositions. From the viewpoint of obtaining an even more excellent pore opening improving effect, the formulation form of the pore opening improving agent of the present invention preferably includes an aqueous gel composition, an oily gel composition, and an emulsified composition, and more preferably. Examples include emulsified compositions. When the pore enlargement improving agent of the present invention is an emulsion composition, the emulsion type may be either an oil-in-water type or a water-in-oil type, but preferably an oil-in-water type.
本発明の毛穴開き改善剤は、毛穴の開きを改善する目的で使用される。具体的には、本発明の毛穴開き改善は、毛穴を収縮させることで毛穴の開きを目立たなくし、それによって視認できる毛穴の数を減らす目的で使用される。 The pore opening improving agent of the present invention is used for the purpose of improving pore opening. Specifically, the pore enlargement improvement of the present invention is used for the purpose of making the pores less noticeable by shrinking the pores, thereby reducing the number of visible pores.
また、本発明の毛穴開き改善剤は、化粧料、外用医薬部外品、外用医薬品等の外用剤として使用することができる。本発明の毛穴開き改善剤の製品形態については、特に制限されないが、例えば、クリーム剤、軟膏剤、乳液剤、ゲル剤、油剤、ローション剤、リニメント剤、エアゾール剤等が挙げられる。これらの中でも、好ましくは、ゲル剤、クリーム剤、軟膏剤、乳液剤、ローション剤が挙げられ、より好ましくは、ゲル剤、クリーム剤が挙げられる。 Further, the pore enlargement improving agent of the present invention can be used as an external preparation such as a cosmetic, an external quasi-drug, or an external pharmaceutical. The product form of the pore size improving agent of the present invention is not particularly limited, but examples include creams, ointments, emulsions, gels, oils, lotions, liniments, aerosols, and the like. Among these, preferred are gels, creams, ointments, emulsions, and lotions, and more preferred are gels and creams.
製造方法
本発明の毛穴開き改善剤は、製剤形態に応じて、公知の製剤化手法に従って製造することができる。例えば、本発明の毛穴開き改善剤の製造方法としては、上記（Ａ）成分及び（Ｂ）成分、必要に応じて配合される他の成分、薬効成分、添加剤等を所望量混合することにより調製される。本発明の毛穴開き改善剤が乳化組成物である場合は、乳化タイプに応じて、公知の乳化製剤の製剤化手法に従って製造することができる。例えば、乳化組成物である場合の本発明の毛穴開き改善剤の製造方法としては、含有させる成分を水溶性成分と油性成分に分けて、水溶性成分を含む水相と、油性成分を含む油相とを調製し、これらを公知の手法に従って乳化させる方法が挙げられる。
Production Method The pore enlargement improving agent of the present invention can be produced according to known formulation techniques depending on the formulation form. For example, the method for producing the pore opening improving agent of the present invention includes mixing the above-mentioned (A) component and (B) component, other components blended as necessary, medicinal ingredients, additives, etc. in desired amounts. prepared. When the pore enlargement improving agent of the present invention is an emulsion composition, it can be manufactured according to known formulation methods for emulsion preparations depending on the emulsion type. For example, the method for producing the pore size improver of the present invention in the case of an emulsified composition involves dividing the components to be contained into a water-soluble component and an oily component, and separating the water phase containing the water-soluble component and the oil phase containing the oily component. Examples include a method of preparing a phase and emulsifying them according to a known method.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES The present invention will be explained in more detail with reference to Examples below, but the present invention is not limited thereto.
試験例
表１に示す乳化型の外用組成物を調製した。具体的には、表１に示す（II）の各成分を６５～８５℃で加熱混合し固形分を溶解させ、更に（Ａ）成分を混合し溶解させて得た水相に、表１に示す（Ｉ）の各成分を６５～８５℃で加熱混合し固形分を溶解させ、更に（
Ｂ）成分を混合し溶解させて得た油相を加えて、ホモミキサーを用いて乳化し、３５℃まで冷却撹拌することにより、クリーム状の水中油型乳化組成物を製造した。
Test Example An emulsified external composition shown in Table 1 was prepared. Specifically, each component (II) shown in Table 1 was heated and mixed at 65 to 85°C to dissolve the solid content, and then component (A) was mixed and dissolved to obtain an aqueous phase. The components shown in (I) are heated and mixed at 65 to 85°C to dissolve the solid content, and then (
The oil phase obtained by mixing and dissolving the components B) was added, emulsified using a homomixer, and cooled to 35° C. and stirred to produce a creamy oil-in-water emulsion composition.
得られた各毛穴開き改善剤を、５月に、１日1回、１か月間、被験者の頬部に塗布した。塗布前と塗布１か月後における当該頬部表面を、皮膚画像解析装置ＶＩＳＩＡ（株式会社インテグラル）にて等倍視野で視認できる毛穴の数を測定した。塗布前における視認できる毛穴数から塗布後における視認できる毛穴数を差し引いた値を、「視認できる毛穴数の変化量」として導出した。「視認できる毛穴数の変化量」は毛穴開きの改善の度合いを評価する値であり、小さいほど毛穴開きの改善効果が高いことを示す。結果を表１に示す。 Each of the obtained pore enlargement improving agents was applied to the cheeks of the subjects once a day for one month in May. The number of visible pores on the cheek surface before application and one month after application was measured using a skin image analysis device VISIA (Integral Co., Ltd.) under a same magnification field of view. The value obtained by subtracting the number of visible pores after application from the number of visible pores before application was derived as the "amount of change in the number of visible pores". "The amount of change in the number of visible pores" is a value for evaluating the degree of improvement in pore enlargement, and the smaller the value, the higher the pore enlargement improvement effect. The results are shown in Table 1.
表１から明らかなように、比較例１では、視認できる毛穴の数が増大し、毛穴開きが悪化し、更に、パンテノールを単独で含む場合（比較例２）及びウフェナマートを単独で含む場合（比較例３）でも毛穴開きの悪化が認められた一方で、パンテノールとウフェナマートとを含む場合（実施例１～５）では、視認できる毛穴の数が減少し、毛穴開きの改善が認められた。また、パンテノール又はパントテン酸と５重量％以上のウフェナマートとを含む場合（実施例３～５）では視認できる毛穴の数が劇減し、毛穴開きの劇的な改善が認められた。 As is clear from Table 1, in Comparative Example 1, the number of visible pores increased and pore opening worsened, and further, in the case of containing panthenol alone (Comparative Example 2) and the case of containing ufenamate alone ( Comparative Example 3) also showed worsening of pore enlargement, while in cases containing panthenol and ufenamate (Examples 1 to 5), the number of visible pores decreased and improvement in pore enlargement was observed. . Furthermore, in cases where panthenol or pantothenic acid and 5% by weight or more of ufenamate were included (Examples 3 to 5), the number of visible pores was dramatically reduced, and a dramatic improvement in pore size was observed.
処方例
表２に示す処方の乳化型の外用組成物を、上記試験例と同様にして調製した。いずれの処方の外用組成物も、優れた毛穴開きの改善効果が認められた。
Formulation Example An emulsified external composition having the formulation shown in Table 2 was prepared in the same manner as in the above Test Example. Excellent effects on improving enlarged pores were observed in all formulations of the external compositions.
Claims (6)
The pore enlargement improving agent according to any one of claims 1 to 5, which is an emulsified composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019112052A JP7421874B2 (en) | 2019-06-17 | 2019-06-17 | Open pore improver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019112052A JP7421874B2 (en) | 2019-06-17 | 2019-06-17 | Open pore improver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020203849A JP2020203849A (en) | 2020-12-24 |
| JP7421874B2 true JP7421874B2 (en) | 2024-01-25 |
Family
ID=73837829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019112052A Active JP7421874B2 (en) | 2019-06-17 | 2019-06-17 | Open pore improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7421874B2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010270029A (en) | 2009-05-20 | 2010-12-02 | Shiseido Co Ltd | Oil-in-water type emulsified skin care preparation for external use |
| JP2011256292A (en) | 2010-06-10 | 2011-12-22 | Shiseido Co Ltd | Application of ufenamate, and skin care composition for ultraviolet protection blending the same |
| JP2012031068A (en) | 2010-07-28 | 2012-02-16 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2012031116A (en) | 2010-08-02 | 2012-02-16 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
-
2019
- 2019-06-17 JP JP2019112052A patent/JP7421874B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010270029A (en) | 2009-05-20 | 2010-12-02 | Shiseido Co Ltd | Oil-in-water type emulsified skin care preparation for external use |
| JP2011256292A (en) | 2010-06-10 | 2011-12-22 | Shiseido Co Ltd | Application of ufenamate, and skin care composition for ultraviolet protection blending the same |
| JP2012031068A (en) | 2010-07-28 | 2012-02-16 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2012031116A (en) | 2010-08-02 | 2012-02-16 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
Non-Patent Citations (3)
| Title |
|---|
| Anti-Inflammatory Cream, Kobayashi Pharmaceutical, 2018年5月, Mintel GNPD [online]，[検索日 2023.03.15], インターネット<URL:https://www.gnpd.com>, ID:5669481 |
| ペンタフォームジャパン株式会社「アルプ－シーバム」，FRAGRANCE JOURNAL，2007年11月，p.114-115 |
| 青島央江、ほか，目立つ毛穴に対するフラーレンの効果，FRAGRANCE JOURNAL，2017年02月，p.46-49 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020203849A (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1633313B1 (en) | Lipid composition and skin care formulation containing the same | |
| ES2565317T3 (en) | Topical skin care composition | |
| JP5342736B2 (en) | Oil-in-water emulsion and method for producing the same | |
| JP6753312B2 (en) | Topical skin preparation for medical use | |
| TWI806867B (en) | Emulsion composition | |
| JP7421874B2 (en) | Open pore improver | |
| JP6967369B2 (en) | Emulsifying composition | |
| JP2023073433A (en) | Emulsion composition for external use | |
| JPWO2019240290A1 (en) | Topical composition | |
| JP6817733B2 (en) | Preparation for internal bleeding treatment | |
| JP7479127B2 (en) | External Composition | |
| JP2016179958A (en) | Skin pigmentation inhibitor | |
| JP2002205937A (en) | Emulsified composition | |
| JP7312527B2 (en) | emulsion composition | |
| JP7464358B2 (en) | Emulsion composition | |
| JP2018002685A (en) | Emulsion composition | |
| JP2024029227A (en) | External composition | |
| JP7092495B2 (en) | External composition for suppressing pigmentation | |
| JP7329910B2 (en) | Skin topical composition | |
| JPH10114642A (en) | Skin preparation for external use | |
| WO2020137683A1 (en) | Composition for external use | |
| JP2003238383A (en) | Skin care preparation | |
| JP6735587B2 (en) | External composition | |
| JP2017171643A (en) | External composition | |
| JP2023058473A (en) | External composition for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220526 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230322 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231204 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7421874 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |